• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

如何建立合作伙伴关系,将创新药物带给患者。

How partnership should work to bring innovative medicines to patients.

机构信息

The Rhythm of Business, 313 Washington St, Ste 300, Newton, MA 02458, USA.

BioArctic AB, Warfvinges väg 35, SE-112 51 Stockholm, Sweden.

出版信息

Drug Discov Today. 2020 Jun;25(6):965-968. doi: 10.1016/j.drudis.2020.03.004. Epub 2020 Mar 12.

DOI:10.1016/j.drudis.2020.03.004
PMID:32173523
Abstract

Scientists increasingly find themselves working in bilateral drug development alliances. Alliances are conceptually simple, but operationally challenging, resulting in the value-eroding misalignment and delays that alliances often experience. This case study of an exemplary collaboration between a small biotech and a global biopharmaceutical company is based on 15 interviews and a lessons-learned workshop conducted with the principal alliance team members. We outline five repeatable practices identified as contributing to their success that other alliance teams can follow.

摘要

科学家们越来越多地发现自己在双边药物开发联盟中工作。联盟在概念上很简单,但在操作上具有挑战性,导致联盟经常出现价值减损的错位和延迟。这项对小型生物技术公司和大型制药公司之间杰出合作的案例研究基于对主要联盟团队成员的 15 次访谈和一次经验教训研讨会。我们概述了五个可重复的实践经验,这些经验被认为有助于他们取得成功,其他联盟团队可以效仿。

相似文献

1
How partnership should work to bring innovative medicines to patients.如何建立合作伙伴关系,将创新药物带给患者。
Drug Discov Today. 2020 Jun;25(6):965-968. doi: 10.1016/j.drudis.2020.03.004. Epub 2020 Mar 12.
2
Pharma blockchains AI for drug development.用于药物研发的制药区块链人工智能。
Lancet. 2019 Jun 15;393(10189):2382. doi: 10.1016/S0140-6736(19)31401-1.
3
Adoption of organ-on-chip platforms by the pharmaceutical industry.制药行业对芯片器官平台的采用。
Nat Rev Drug Discov. 2021 Dec;20(12):961-962. doi: 10.1038/s41573-021-00323-0.
4
Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.基准化生物制药工艺开发和制造对研发的成本贡献。
MAbs. 2020 Jan-Dec;12(1):1754999. doi: 10.1080/19420862.2020.1754999.
5
Translational Research and Drug Development in Psoriasis by Collaborative Efforts of Academia and Industry.学术界与产业界合作开展的银屑病转化研究与药物研发
J Invest Dermatol. 2020 Mar;140(3):524-526. doi: 10.1016/j.jid.2020.01.002. Epub 2020 Jan 13.
6
Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019.利用制剂和临床药理学知识提高儿科药物研发效率:M-CERSI 儿科制剂研讨会 2019 概述和讨论。
Eur J Pharm Biopharm. 2021 Jul;164:66-74. doi: 10.1016/j.ejpb.2021.04.010. Epub 2021 Apr 18.
7
How to develop therapeutic and translational research collaborations with industry.如何与业界开展治疗和转化研究合作。
Mol Biol Cell. 2019 Oct 15;30(22):2741-2743. doi: 10.1091/mbc.E19-05-0261.
8
The perceived importance of intersectoral collaboration by health care alliances.卫生保健联盟对跨部门合作的认知重要性。
J Community Psychol. 2019 May;47(4):856-868. doi: 10.1002/jcop.22158. Epub 2019 Jan 21.
9
Impact of the Innovative Medicines Initiative on vaccine development.创新药物倡议对疫苗研发的影响。
Nat Rev Drug Discov. 2018 Nov;17(11):769-770. doi: 10.1038/nrd.2018.72. Epub 2018 Jun 1.
10
An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies.药企间视角下的生物制药药物产品稳健性研究。
J Pharm Sci. 2018 Feb;107(2):529-542. doi: 10.1016/j.xphs.2017.10.017. Epub 2017 Oct 23.

引用本文的文献

1
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency.英国和日本制药行业支付披露的国际比较:对自我监管、公共监管和透明度的影响。
Global Health. 2023 Mar 3;19(1):14. doi: 10.1186/s12992-022-00902-9.